Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

MediPharm Labs Q1 2026: revenue falls, adjusted EBITDA positive for first time

MediPharm Labs reported Q1 2026 revenue of CAD 9.0 million (‑16.7% year‑on‑year) but achieved a positive adjusted EBITDA of CAD 0.1 million. Net loss widened to CAD 0.9 million, gross margin was 37%. International revenue accounted for 51% of sales. The company plans annual savings of CAD 1.0 million through restructurings and holds CAD 9.9 million in cash. The stock rose 12.5% in pre-market trading after the results were released. » Altro su de.investing.com
MediPharm Labs beats Q4 revenue forecast by 5.79% and highlights international sales

MediPharm Labs reported Q4 2025 revenue of CAD 14.06 million versus expected CAD 13.29 million (+5.79%) and an EPS of zero, in line with forecasts. The stock rose 7.69% in premarket trading. International medical cannabis sales contributed over 50% of total revenue; the fiscal year recorded revenue growth of 8% and an improved net loss position of CAD 8.3 million. The company emphasizes expansion into foreign markets and the expansion of EU‑GMP capacity for 2026. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2022, MediPharm Labs ha già distribuito 0,0431€ di dividendi. L'ultimo pagamento è avvenuto a aprile 2022.

Dati finanziari dell'azienda

Nell'ultimo trimestre, MediPharm Labs ha registrato ricavi pari a 6,16M€ e un utile netto di 2,47k€

(EUR)	giu 2026	YoY
Ricavi	+6,16M	16,34%
Utile lordo	+2,65M	27,56%
Utile netto	+2,47k	100,10%
EBITDA	+136,35k	106,55%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+20,42M€
Numero di azioni	424,86M
Massimo/minimo a 52 settimane	+0,0652€ - +0,0352€
Dividendi	No
Beta	0,95
Rapporto P/E	−6,90
Rapporto PEG	−0,10
Rapporto P/B	+0,96
Rapporto P/S	+0,82

Profilo aziendale

MediPharm Labs Corp. ist ein pharmazeutisches Unternehmen, das Cannabisöl und -konzentrate in pharmazeutischer Qualität sowie fortschrittliche derivative Produkte in Kanada, Australien, Deutschland und international herstellt und vertreibt. Das Unternehmen formuliert, verarbeitet, verpackt und vertreibt Cannabisextrakte und fortschrittliche Produkte auf Cannabinoidbasis. Das Unternehmen bietet auch GMP-Blumenbeschaffung, Verpackung und Vertriebsdienstleistungen an. MediPharm Labs Corp. wurde im Jahr 2015 gegründet und hat seinen Hauptsitz in Barrie, Kanada.